

Soy Food Consumption and Breast Cancer Prognosis

Bette J. Caan¹, Loki Natarajan², Barbara Parker², Ellen B. Gold³, Cynthia Thomson⁴, Vicky Newman², Cheryl L. Rock², Minya Pu², Wael Al-Delaimy², and John P. Pierce²

Abstract

Background: Contrary to earlier clinical studies suggesting that soy may promote breast tumor growth, two recent studies show that soy-containing foods are not adversely related to breast cancer prognosis. We examined, using data from the Women's Healthy Eating and Living (WHEL) study, the effect of soy intake on breast cancer prognosis.

Methods: Three thousand eighty-eight breast cancer survivors, diagnosed between 1991 and 2000 with early-stage breast cancer and participating in WHEL, were followed for a median of 7.3 years. Isoflavone intakes were measured postdiagnosis by using a food frequency questionnaire. Women self-reported new outcome events semiannually, which were then verified by medical records and/or death certificates. HRs and 95% CIs representing the association between either a second breast cancer event or death and soy intake were computed, adjusting for study group and other covariates, using the delayed entry Cox proportional hazards model.

Results: As isoflavone intake increased, risk of death decreased (P for trend = 0.02). Women at the highest levels of isoflavone intake (>16.3 mg isoflavones) had a nonsignificant 54% reduction in risk of death.

Conclusion: Our study is the third epidemiologic study to report no adverse effects of soy foods on breast cancer prognosis.

Impact: These studies, taken together, which vary in ethnic composition (two from the United States and one from China) and by level and type of soy consumption, provide the necessary epidemiologic evidence that clinicians no longer need to advise against soy consumption for women with a diagnosis of breast cancer. *Cancer Epidemiol Biomarkers Prev*; 20(5); 854–8. ©2011 AACR.

Introduction

Soy foods, a major source of phytoestrogens show both antiestrogenic and estrogen-like properties. Many studies have shown that soy consumption may protect against breast cancer, whereas other studies have shown that isoflavones, the major component of soy, enhance the proliferation of breast cancer cells *in vitro* (1), promote mammary tumor growth in rats (2), and possibly interfere with the effectiveness of tamoxifen (3, 4). As a result, clinicians treating women with breast cancer frequently caution them to either avoid soy foods entirely or use them in moderation (2, 5, 6).

To add to the uncertainty, 2 recent epidemiologic studies examining breast cancer survivors, 1 in Asian

women from the Shanghai Breast Cancer Survival Study (SBCS; ref. 7) and 1 in U.S. women from the Life After Cancer Epidemiology (LACE) study (8), suggest that soy-containing foods do not adversely affect breast cancer prognosis, do not counteract the benefits of tamoxifen and may, in fact, offer some potential benefits in decreasing risk of recurrence or death from breast cancer. Before clinical recommendations can be made, these findings need to be replicated in other large cohorts with longer follow-up. We have explored this question further in secondary analyses by using data from the Women's Healthy Eating and Living (WHEL) study, a randomized controlled trial of a high fruit/vegetable/fiber and low fat dietary intervention in early-stage breast cancer survivors in the United States.

Materials and Methods

The WHEL study population has been previously described (9). Briefly, 3,088 breast cancer survivors with a diagnosis between 1991 and 2000 who participated in a dietary intervention trial were followed throughout and after completion of the trial that ended in 2006. Enrolled participants had a diagnosis of and completed treatment (within the previous 4 years) of stage I, II, or III (AJCC VI classification) invasive breast cancer. Participants were 18

Authors' Affiliations: ¹Division of Research, Kaiser Permanente, Oakland; ²Moore's Cancer Center, University of California, San Diego, La Jolla; ³Department of Public Health Sciences, UC Davis School of Medicine, Davis, California; and ⁴Department of Nutritional Sciences, Arizona Cancer Center, University of Arizona, Tucson, Arizona

Corresponding Author: Bette J. Caan, Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612. Phone: 510-891-3719; Fax: 510-891-3836. E-mail: bette.caan@kp.org

doi: 10.1158/1055-9965.EPI-10-1041

©2011 American Association for Cancer Research.

to 70 years of age and had no evidence of disease within the 12 months prior to study enrollment. During semi-annual telephone interviews, women were queried about the occurrence of new outcome events. Any report of a breast cancer event was confirmed by medical records and/or death certificates and oncologist review. Finally, we searched the National Death Index by using Social Security Number, name, and date of birth to confirm cause of death.

Women included in this study had a median follow-up of 7.3 years from the time of enrollment. Soy intake (milligrams of isoflavones) was measured postdiagnosis (median 2 years, range: 2 months to 4 years) at study entry by using the Arizona Food Frequency Questionnaire (AFFQ), a 153-item semiquantitative, scannable questionnaire (10, 11) that included specific line items for "Meat Substitutes (such as Tofu, Veggie Burgers)" and "Soy Milk," as well as an opportunity to include other soy food items on the "additional foods" list portion of the food frequency questionnaire (FFQ). Modified from the Block-National Cancer Institute Health Habits and History Questionnaire, the AFFQ, which has previously been validated against both 4-day food records (11) and 24-hour recalls (10), elicits information about the usual foods consumed and the frequency of consumption, using age- and gender-specific estimates of portions estimated as small, medium, or large.

In addition, information on soy supplement use since diagnosis was obtained by a separate questionnaire (12) asking respondents about the frequency and duration of use by using an extensive list of supplements and herbs and allowing participants to report their supplements not listed on the predetermined list in an open-ended question. A yes/no use variable was created, as the responses indicating the frequency and duration of soy supplement use were low.

Daily isoflavone intake, derived from totaling isoflavone intake across all line items in the FFQ, was generated using the USDA-Iowa State University Database on the Isoflavone Content of Foods (13). Isoflavone contents of foods in the USDA database were collected from scientific articles published in refereed journals and were generated by extensive sampling of soy-containing foods and subsequent analysis at Iowa State University.

Data analyses

Women were divided into 4 groups, with the highest category (upper 5th percentile: 6.3–86.9 mg/d) representing intakes similar to those consumed in Asian populations. Delayed entry multiple Cox proportional hazards models (14) were developed and HRs and 95% CIs representing the association between either a second breast cancer event or all-cause mortality and level of soy intake were computed. A second breast cancer event included both local and distant recurrences and new breast primaries. All cause mortality included death due to any cause, although 81% of the deaths were due to breast cancer. The models were adjusted for

randomization group, soy supplement use, and other demographic and clinical covariates known to be associated with breast cancer outcomes. Score tests were used to assess trends across quintiles. Residual plots were used to examine model fit. Likelihood ratio tests were used to examine interactions between isoflavone intake and each of tamoxifen use and estrogen receptor (ER)/progesterone receptor (PR) status, to examine whether these factors modified the association between isoflavones and outcomes. The software package R was used for all statistical analysis (15).

Results

Baseline isoflavone intakes did not differ between the intervention and control groups. Among women in the intervention and control groups, 19.2% and 20.8%, respectively, consumed greater than 10.1 mg of isoflavones daily (data not shown). Isoflavone intake differed by age, race/ethnicity, and education but did not differ by tamoxifen use, hormone receptor status, or menopausal status. Younger women, Asians, and women with a college degree or higher were the most likely to consume soy in the upper category (Table 1). Isoflavone intake was unrelated to the risk of a second breast cancer event overall or within strata of women defined by hormone receptor status or whether they ever used tamoxifen (Table 2). Furthermore, no significant increased or decreased risk was associated with any level of intake within strata (Table 2). In contrast, for overall mortality, risk of death tended to be lower as isoflavone intake increased (P for trend = 0.02). Women at the highest levels of isoflavone intake (>16.3 mg isoflavones, equivalent to at least one-half cup soymilk or 2-oz tofu each day) had a nonsignificant 54% reduction in risk of death compared with the lowest quintile of soy intake. Although the interaction between soy intake and tamoxifen use on mortality was not statistically significant (Table 2), the observed trend toward lower mortality with increased soy seemed stronger in women who had ever used tamoxifen (P for trend = 0.05). The trend toward lower mortality with increasing soy did not differ by hormone receptor status of the tumor. Sensitivity analyses were conducted by repeating the analysis restricted to the subgroup of women who were currently (at baseline) taking tamoxifen ($N = 1,642$); the results did not change (data not shown).

Discussion

Our study is now the third epidemiologic study in the recent past to report no adverse effects of soy food intake on breast cancer recurrence (7, 8) or total mortality (7) either alone or in combination with tamoxifen (7, 8). Contrary to soy being harmful, these recent reports, to varying degrees, suggest possible benefits for breast cancer survivors.

Table 1. The number and percentage of women enrolled in WHEL across isoflavone category by demographic, medical, and tumor characteristics

Baseline characteristics	Soy isoflavone intake, mg/d				P
	Level 1 (0–0.7), median = 0	Level 2 (0.7–1.01), median = 0.3	Level 3 (1.01–16.33), median = 4.8	Level 4 (16.33–86.9), median = 26.7	
	n (%)	(%)	(%)	(%)	
Age, y					0.008
<45	182 (37.9)	192 (40)	80 (16.7)	26 (5.4)	
45–54	440 (39)	441 (39.1)	180 (15.9)	68 (6)	
55–60	179 (37.9)	194 (41.1)	75 (15.9)	24 (5.1)	
≥60	294 (44.9)	267 (40.8)	75 (11.5)	19 (2.9)	
Race/ethnicity					<0.001
White	910 (39.0)	951 (40.7)	350 (15)	123 (5.3)	
Black	69 (65.7)	26 (24.8)	9 (8.6)	1 (1)	
Hispanic	91 (61.1)	42 (28.2)	12 (8.1)	4 (2.7)	
Asian	8 (9.5)	45 (53.6)	27 (32.1)	4 (4.8)	
Other ^a	17 (26.6)	30 (46.9)	12 (18.8)	5 (7.8)	
Education					<0.001
Some college	625 (50.2)	455 (36.6)	128 (10.3)	36 (2.9)	
College degree or higher	470 (31.5)	639 (42.8)	282 (18.9)	101 (6.8)	
Menopausal status					0.189
Post- or perimenopausal	985 (40.6)	967 (39.9)	357 (14.7)	117 (4.8)	
Premenopausal	108 (35.3)	126 (41.2)	52 (17)	20 (6.5)	
Baseline tamoxifen use					0.321
Current	646 (39.3)	668 (40.7)	247 (15)	81 (4.9)	
Never	376 (42.5)	334 (37.8)	128 (14.5)	46 (5.2)	
Past	59 (33.9)	81 (46.6)	27 (15.5)	7 (4)	
ER/PR status					0.127
ER ⁺ or PR ⁺	835 (38.9)	865 (40.3)	331 (15.4)	113 (5.3)	
ER ⁻ /PR ⁻	238 (43.6)	214 (39.2)	74 (13.6)	20 (3.7)	
Stage					0.25
I	430 (40.5)	438 (41.2)	143 (13.5)	52 (4.9)	
II	495 (39.5)	489 (40.0)	202 (16.1)	68 (5.4)	
III	170 (40.6)	167 (39.9)	65 (15.5)	17 (3.3)	
Isoflavone supplements ^b					0.001
Yes	17 (29.3)	16 (27.6)	18 (31)	7 (12.1)	
No	1,078 (40.3)	1,078 (40.3)	392 (14.6)	130 (4.9)	

^aPacific Islander, American Indian/mixed race.

^bP value for differences of isoflavone intake between strata within category.

Although the mean soy intake in the WHEL population is much lower than that observed among Chinese women in the SBCS (7), the suggested protective associations seen with total mortality for women in WHEL at the highest soy intake level are comparable with what was seen for Chinese women consuming similar levels of isoflavones. Similar to results from both the SBCS study (7) and the LACE study (8), the largest benefits associated with soy consumption in our study were seen in women who used tamoxifen. Continued research is needed to further understand and

confirm these relationships, as in WHEL, power to detect associations at the highest level of soy intake was limited.

Strengths of the WHEL study include being one of the few existing studies of early-stage breast cancer survivors with long-term follow-up on both recurrence and survival and information on postdiagnosis soy food intake. Although our analyses relied on self-report of soy food intake from the AFFQ, several validation studies have reported that assessment of soy intake by FFQs that use soymilk and tofu alone

Table 2. Adjusted^a HRs and 95% CIs for breast cancer recurrence and mortality for levels of isoflavone intake at baseline (all women and stratified by tamoxifen use and hormone receptor status) for women enrolled in WHEL

	<i>N</i>	No. of new breast cancer events	HR (95% CI) for new invasive breast cancer event ^b (<i>n</i> = 448)	No. of deaths	HR (95% CI) for overall mortality (<i>n</i> = 271)
<i>All women (n = 2,736)</i>					
Total isoflavones, mg/d					
Level 1 (0–0.07)	1,095	190	Reference: 1	133	Reference: 1
Level 2 (0.07–1.01)	1,094	167	0.89 (0.72–1.11)	95	0.75 (0.57–0.99)
Level 3 (1.01–16.33)	410	73	0.99 (0.75–1.32)	37	0.79 (0.54–1.15)
Level 4 (16.33–86.9)	137	18	0.78 (0.46–1.31)	6	0.46 (0.2–1.05)
			<i>P</i> for trend = 0.47		<i>P</i> for trend = 0.02
<i>Women who used tamoxifen (n = 1,816)</i>					
Total isoflavones, mg/d					
Level 1 (0–0.07)	705	112	Reference: 1	79	Reference: 1
Level 2 (0.07–1.01)	749	106	0.91 (0.69–1.21)	64	0.79 (0.56–1.12)
Level 3 (1.01–16.33)	274	44	0.97 (0.67–1.41)	23	0.81 (0.5–1.3)
Level 4 (16.33–86.9)	88	8	0.59 (0.27–1.29)	2	0.26 (0.06–1.08)
			<i>P</i> for trend = 0.35		<i>P</i> for trend = 0.05
<i>Nonusers of tamoxifen (n = 884)</i>					
Isoflavones, mg/d					
Level 1 (0–0.07)	376	77	Reference: 1	53	Reference: 1
Level 2 (0.07–1.01)	334	58	0.82 (0.57–1.17)	28	0.61 (0.38–0.99)
Level 3 (1.01–16.33)	128	28	1.09 (0.69–1.71)	13	0.79 (0.42–1.49)
Level 4 (16.33–86.9)	88	10	0.96 (0.46–1.99)	4	0.68 (0.24–1.99)
			<i>P</i> for trend = 1.0		<i>P</i> for trend = 0.20
Interaction between tamoxifen and isoflavones					
			<i>P</i> for interaction = 0.54		<i>P</i> for interaction = 0.45
<i>Women with tumors that were ER⁺ or PR⁺ (n = 2,144)</i>					
Level 1 (0–0.07)	835	137	Reference: 1	93	Reference: 1
Level 2 (0.07–1.01)	865	125	0.9 (0.7–1.16)	70	0.76 (0.55–1.05)
Level 3 (1.01–16.33)	331	58	1.06 (0.77–1.46)	30	0.91 (0.59–1.39)
Level 4 (16.33–86.9)	113	14	0.84 (0.47–1.51)	3	0.31 (0.1–0.98)
			<i>P</i> for trend = 0.83		<i>P</i> for trend = 0.07
<i>Women with tumors that were ER⁻/PR⁻ (n = 546)</i>					
Level 1 (0–0.07)	238	50	Reference: 1	38	Reference: 1
Level 2 (0.07–1.01)	214	39	0.78 (0.5–1.22)	24	0.62 (0.36–1.07)
Level 3 (1.01–16.33)	74	14	0.79 (0.42–1.49)	7	0.46 (0.19–1.1)
Level 4 (16.33–86.9)	20	3	0.62 (0.19–2.03)	3	0.86 (0.25–2.9)
			<i>P</i> for trend = 0.25		<i>P</i> for trend = 0.10
Interaction between receptor status and isoflavones					
			<i>P</i> for interaction = 0.91		<i>P</i> for interaction = 0.31

^aModels adjusted for stage, grade, ER/PR status, menopausal status, chemotherapy treatment, radiation, age, education, race, soy supplements intervention group, presence of hot flash symptoms, and their interaction; the unstratified model was also adjusted for tamoxifen use; the model subset to women not taking tamoxifen did not adjust for race because of small cell sizes.

^bNew breast cancer event includes an invasive breast cancer recurrence or a new invasive primary breast cancer.

correlates well with isoflavone biomarkers either in blood or in urine (16–19). In one study of U.S. adults (17), in which they compared a soy-specific 40-item FFQ to the more general 122-item WHI FFQ and examined intakes from both with plasma concentrations, they found that isoflavone intake was highly correlated between the 2 FFQ instruments ($r = 0.84$) and that isoflavone intake derived from both instruments were significantly correlated with plasma concentration of isoflavones. They also found that soymilk and tofu were the 2 major contributors to isoflavone intake and accounted for approximately 40% of total intake.

Because the WHEL cohort consists of early-stage breast cancer survivors who were enrolled on average 2 years after diagnosis, our results are not generalizable to women with a diagnosis of advanced-stage breast cancer and apply only to women who have survived, on average, 2 years since diagnosis.

References

1. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of *in vitro*, preclinical, and clinical studies. *Nutr Rev* 2009;67:398–415.
2. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. *Inflammopharmacology* 2008;16:219–26.
3. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. *Cancer Res* 2002;62:2474–7.
4. Schwartz JA, Liu G, Brooks SC. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. *Biochem Biophys Res Commun* 1998;253:38–43.
5. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. *CA Cancer J Clin* 2006;56:323–53.
6. Velentzis LS, Woodside JV, Cantwell MM, Leatham AJ, Keshtgar MR. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. *Eur J Cancer* 2008;44:1799–806.
7. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, et al. Soy food intake and breast cancer survival. *JAMA* 2009;302:2437–43.
8. Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ, et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat* 2009;118:395–405.
9. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. *JAMA* 2007;298:289–98.
10. Thomson CA, Giuliano A, Rock CL, Ritenbaugh CK, Flatt SW, Faerber S, et al. Measuring dietary change in a diet intervention trial: comparing food frequency questionnaire and dietary recalls. *Am J Epidemiol* 2003;157:754–62.
11. Martínez ME, Marshall JR, Graver E, Whitacre RC, Woolf K, Ritenbaugh C, et al. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. *Cancer Epidemiol Biomarkers Prev* 1999;8:941–6.
12. Newman V, Rock CL, Faerber S, Flatt SW, Wright FA, Pierce JP, et al. Dietary supplement use by women at risk for breast cancer recurrence. The Women's Healthy Eating and Living Study Group. *J Am Diet Assoc* 1998;98:285–92.
13. Nutrient Data Laboratory. USDA-Iowa State University Database on the Isoflavone Content of Foods, Release 1.3 – 2002 [cited 2002]. Available from: <http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isoflav.html>.
14. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. New York: Springer-Verlag; 2000.
15. R-Project.org [Internet]. Vienna: Vienna University of Economics and Business, Institute for Statistics and Mathematics c2011 [updated 2009 May 13; access 2010 Nov 1]. Available from: <http://www.r-project.org/>.
16. Frankenfeld CL, Patterson RE, Horner NK, Neuhauser ML, Skor HE, Kalhorn TF, et al. Validation of a soy food-frequency questionnaire and evaluation of correlates of plasma isoflavone concentrations in postmenopausal women. *Am J Clin Nutr* 2003;77:674–80.
17. Frankenfeld CL, Patterson RE, Kalhorn TF, Skor HE, Howald WN, Lampe JW, et al. Validation of a soy food frequency questionnaire with plasma concentrations of isoflavones in US adults. *J Am Diet Assoc* 2002;102:1407–13.
18. Jaceldo-Siegl K, Fraser GE, Chan J, Franke A, Sabate J. Validation of soy protein estimates from a food-frequency questionnaire with repeated 24-h recalls and isoflavonoid excretion in overnight urine in a Western population with a wide range of soy intakes. *Am J Clin Nutr* 2008;87:1422–7.
19. Williams AE, Maskarinec G, Hebshi S, Oshiro C, Murphy S, Franke AA, et al. Validation of a soy questionnaire with repeated dietary recalls and urinary isoflavone assessments over one year. *Nutr Cancer* 2003;47:118–25.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 05, 2010; revised January 24, 2011; accepted February 7, 2011; published OnlineFirst February 25, 2011.